O78: SARCOPENIA IN LOCALLY ADVANCED BREAST CANCER: PREVALENCE, AND IMPACT ON CLINICAL AND ONCOLOGIC OUTCOMES

Abstract Introduction Sarcopenia in cancer may confer negative outcomes, but its prevalence and impact the modern multimodal management of locally advanced breast have not been systematically studied. Method Patients undergoing neoadjuvant therapy surgery for between 2010 2015 were Skeletal muscle index (SMI) lean body mass (LBM) determined. was defined by computed tomography (CT) at L3 as SMI<38.5cm2/m2. Multivariable linear, logistic, Cox regression analysis undertaken to determine independent sarcopenia on clinical oncologic outcome. Result 258 patients present 23.0%, 7.8% 0.0% with normal weight, overweight obesity, respectively (P=0.001). associated baseline cT cN stage, tumour grade, histologic type or receptor status. exhibited equivalent indices response including ypT ypN pathologic complete Sataloff grade following surgical resection. Postoperatively, independently comprehensive complications (P=0.242), length stay (P=0.716) overall morbidity (P=0.365). However, multivariable analysis, lower LBM predicted reduced invasive disease-free (P=0.049,HR0.93[95%CI0.87-1.00]) (P=0.028,HR0.92[0.85-0.99]), disease-specific survival (P=0.070). Conclusion Consistent a lack association post-treatment features, is overall, disease-specific, survival. These data indicate that prognostic be mediated impaired performance status increased non-cancer mortality. Take-home message